Olfr676, encoded by the Or52e7 gene, is an olfactory receptor in the house mouse (Mus musculus), classified within the extensive family of G-protein-coupled receptors (GPCRs). Olfactory receptors like Olfr676 are integral to the sense of smell, detecting odorant molecules in the nasal epithelium and initiating a neuronal response that culminates in olfactory perception. These receptors are structurally characterized by their 7-transmembrane domain, which enables them to interact with various ligands and transduce these interactions into cellular responses. The activation of olfactory receptors by specific odorants triggers G protein-mediated signal transduction, often leading to changes in second messengers such as cyclic AMP (cAMP). The complexity of GPCR signaling pathways, including those of olfactory receptors, makes direct inhibition of Olfr676 challenging. Therefore, the focus shifts to potential indirect inhibitors, targeting processes and pathways that intersect with GPCR signaling. Beta-adrenergic receptor antagonists like propranolol, atenolol, and metoprolol reduce cellular cAMP levels, a crucial second messenger in GPCR signaling. This reduction in cAMP may indirectly influence the signaling pathways of GPCRs like Olfr676. Calcium channel blockers, such as nifedipine and verapamil, modulate intracellular calcium levels, another vital factor in GPCR signaling. Changes in calcium dynamics can indirectly affect the function of GPCRs, including olfactory receptors.
Additionally, targeting other GPCR pathways, such as those modulated by angiotensin II receptors, offers an indirect method to influence olfactory receptor function. Antagonists like losartan and candesartan may alter the GPCR signaling environment, potentially affecting the function of receptors like Olfr676. Alpha-2 adrenergic receptor modulation by agents such as yohimbine and clonidine might also indirectly impact the signaling mechanisms of GPCRs, including olfactory receptors. In conclusion, the indirect inhibition of Olfr676 involves an understanding of the broader GPCR biology and the interconnected nature of cellular signaling pathways. The listed chemicals provide insights into potential mechanisms for influencing the activity of olfactory receptors like Olfr676. While direct inhibition poses significant challenges, these indirect approaches offer avenues for potentially modulating the receptor's function within the complex network of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a non-selective beta-adrenergic antagonist that lowers cAMP levels by inhibiting beta-adrenergic receptors, potentially affecting GPCR-mediated pathways, including those of Olfr676. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $77.00 $408.00 | 1 | |
Atenolol, a selective β1-adrenergic receptor antagonist, decreases cAMP levels, potentially influencing GPCR signaling pathways and indirectly affecting Olfr676. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $105.00 $238.00 | 3 | |
Metoprolol, a β1-adrenergic receptor blocker, might indirectly affect GPCR signaling by altering β1 receptor activity, potentially impacting Olfr676 signaling. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine, a calcium channel blocker, modifies intracellular calcium levels, potentially influencing GPCR-mediated pathways and indirectly affecting Olfr676. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil, a calcium channel blocker, can indirectly influence GPCR signaling through altered calcium dynamics, potentially impacting Olfr676. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Carvedilol, with its beta-adrenergic antagonist and alpha-1 blocking activity, may modulate GPCR-mediated signaling, potentially influencing Olfr676. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, impacts GPCR signaling by inhibiting AT1 receptors, potentially indirectly affecting Olfr676. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $46.00 $92.00 $148.00 | 6 | |
Candesartan, an angiotensin II receptor blocker, might indirectly modulate GPCR signaling, potentially influencing Olfr676. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $50.00 $168.00 $520.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, can indirectly affect GPCR signaling, potentially influencing Olfr676. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $180.00 | ||
Nadolol, a non-selective beta-adrenergic receptor blocker, indirectly influences GPCR signaling, which could impact Olfr676. | ||||||